LON:HIK

Hikma Pharmaceuticals Share Forecast, Price & News

GBX 2,387
-61.00 (-2.49 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
2,387
2,454
50-Day Range
2,301
2,512
52-Week Range
2,086.49
2,768
Volume796,363 shs
Average Volume398,230 shs
Market Capitalization£5.52 billion
P/E Ratio18.59
Dividend Yield1.50%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Hikma Pharmaceuticals logo

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.48 out of 5 stars

Analyst Opinion: 2.5Community Rank: 2.8Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

Is Hikma Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Hikma Pharmaceuticals stock.
View analyst ratings for Hikma Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Hikma Pharmaceuticals?

Wall Street analysts have given Hikma Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hikma Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Hikma Pharmaceuticals
.

How has Hikma Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at GBX 1,828.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HIK shares have increased by 30.5% and is now trading at GBX 2,387.
View which stocks have been most impacted by COVID-19
.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, February 25th. Shareholders of record on Thursday, March 18th will be given a dividend of GBX 0.34 per share on Monday, April 26th. This represents a dividend yield of 1%. The ex-dividend date is Thursday, March 18th. This is an increase from Hikma Pharmaceuticals's previous dividend of GBX 0.16. The official announcement can be seen at this link.
View Hikma Pharmaceuticals' dividend history
.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals pays an annual dividend of GBX 0.46 per share and currently has a dividend yield of 1.50%. The dividend payout ratio of Hikma Pharmaceuticals is 0.36%. This payout ratio is at a healthy, sustainable level, below 75%.
View Hikma Pharmaceuticals' dividend history.

What price target have analysts set for HIK?

5 analysts have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 2,600 to GBX 2,860. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 2,717.50 in the next twelve months. This suggests a possible upside of 13.8% from the stock's current price.
View analysts' price targets for Hikma Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 64, Pay $3.01M)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 52, Pay $3.72M)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 63, Pay $2.16M)
  • Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 49)
  • Ms. Henriette Nielsen, Exec. VP of Bus. Operations
  • Dr. Shahin Fesharaki, Chief Scientific Officer
  • Mr. Hussein Arkhagha, Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan, Exec. VP of Corp. Devel. and M&A (Age 56)
  • Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi, Exec. VP of Organisational Devel.

Who are some of Hikma Pharmaceuticals' key competitors?

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 2,387.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals has a market capitalization of £5.52 billion and generates £2.34 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

Where are Hikma Pharmaceuticals' headquarters?

Hikma Pharmaceuticals is headquartered at 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.